No Data
Harbin Pharmaceutical Group (SHSE:600664) Hikes 10% This Week, Taking Three-year Gains to 35%
Harbin Pharmaceutical Group (600664.SH): The pharmaceutical products of the affiliated company have passed the consistency evaluation of generic drugs.
On April 15th, Gelonghui reported that Harbin Pharmaceutical Group (600664.SH) announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical General Factory (referred to as "Harbin Pharmaceutical General Factory"), received the Notice of Approval for Supplementary Application of Pharmaceutical from the National Medical Products Administration for injectable cefotaxime [1.5g (calculated as C₂₂H₂₂N₆O₇S₂), notice number: 2025B01609; 1.0g (calculated as C₂₂H₂₂N₆O₇S₂), notice number: 2025B01611], and this product has passed the consistency evaluation of quality and efficacy for generic drugs.
Harbin Pharmaceutical Group (600664.SH): Lactulose oral solution obtained the Pharmaceutical registration certificate.
On April 10, Gelonghui reported that Harbin Pharmaceutical Group (600664.SH) announced that its subsidiary, Harbin Pharmaceutical Group Traditional Chinese Medicine Second Factory, received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for the lactulose oral solution. Lactulose is a disaccharide composed of galactose and fructose, developed by Solvay, a company from the USA, which was later acquired by Abbott Laboratories. The lactulose oral solution was first launched in the Netherlands in 1964, used as a laxative to treat constipation, and can also be used to prevent and treat hyperammonemia caused by various liver diseases as well as hepatic encephalopathy resulting from hyperammonemia.
Harbin Pharmaceutical Group (600664.SH): Has not yet started Business related to Brain-computer Interface.
On March 24, Gelonghui reported that Harbin Pharmaceutical Group (600664.SH) stated on the investor interaction platform that the company focuses on the pharmaceutical health industry, mainly engaged in pharmaceutical research and development, manufacturing, wholesale, and Retail Trade. It is a large domestic high-tech pharmaceutical enterprise that integrates pharmaceutical research and development, manufacturing, and sales. The company has not yet undertaken any related business in Brain-computer Interface. The company closely monitors the innovation and development of cutting-edge technologies in emerging fields, continuously enhancing its core competitiveness.
Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Investors Don't See Light At End Of Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Tunnel And Push Stock Down 26%
